Lyme Disease

Manufacturer claims poor sales forced vaccine off market

Published in TB and Outbreaks Week, April 23rd, 2002

Citing poor sales, the maker of the nation's only Lyme disease vaccine has pulled it off the market.

Lymerix had caused controversy in recent years, as patients who argued they were sickened by the vaccine asked the government to restrict sales and also filed numerous lawsuits against maker GlaxoSmithKline.

But after a year of investigation, the U.S. Food and Drug Administration had found no proof that the vaccine was dangerous and thus did not tell the manufacturer to end sales, an agency spokeswoman said.

"The reason is there's just no demand for it," said GlaxoSmithKline spokeswoman Ramona Dubose.

Lymerix...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-04-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry